Boehm Ryan, Donovan John, Sheth Disha, Durfor Andrew, Roberts Jason, Isayeva Irada
1 Division of Biology, Chemistry, and Material Science (DBCMS), Office of Science and Engineering Laboratories (OSEL), Center for Devices and Radiological Health (CDRH), Food and Drug Administration (FDA), Silver Spring, MD, USA.
2 Penn State College of Medicine, Hershey, PA, USA.
J Diabetes Sci Technol. 2019 Jan;13(1):82-95. doi: 10.1177/1932296818791538. Epub 2018 Aug 3.
Electrochemical enzymatic glucose sensors are intended to measure blood or interstitial fluid glucose concentrations. One class of these glucose sensors are continuous glucose monitors (CGMs), indicated for tracking and trending of glucose concentrations in interstitial fluid and as an adjunct to blood glucose testing. Currently approved CGMs employ a glucose oxidase (GOx) electrochemical detection scheme. Potential interfering agents can impact the accuracy of results obtained by glucose sensors, including CGMs.
Seven sugars, seven sugar alcohols, and three artificial sweeteners were in vitro screened for interference with amperometric glucose oxidase (GOx) sensors at concentrations greater than physiologic concentrations. Galactose was investigated further at physiologically relevant concentrations using a custom amperometric system. Furthermore, glucose and galactose calibration experiments were conducted to facilitate multiple enzyme kinetic analysis approaches (Michaelis-Menten and Hill equation) to understand the potential source and mechanism of interference from galactose.
Under in vitro testing, except for galactose, xylose and mannose, all screened compounds exhibited interference bias, expressed in mean absolute relative difference (MARD), of ⩽ 20% even at concentrations significantly higher than normal physiologic concentrations. Galactose exhibited, CGM-dependent, MARD of 47-72% and was subjected to further testing. The highest recorded mean relative difference (MRD) was 6.9 ± 1.3% when testing physiologically relevant galactose concentrations (0.1-10 mg/dL). Enzyme kinetic analysis provided calculations of maximum reaction rates ( ), apparent Michaelis constants ( ), and Hill equation h parameters for glucose and galactose substrates for the enzymes in the CGMs.
Under the conditions of in vitro screening, 14 of the 17 compounds did not exhibit measuarable interference. Galactose exhibited the highest interference during screening, but did not substantially interfere with CGMs under the conditions of in vitro testing at physiologically relevant concentrations. Enzyme kinetic analysis conducted with galactose supported the notion that (1) the reactivity of GOx enzyme toward nonglucose sugars and (2) the presence of enzymatic impurities (such as galactose oxidase) are two potential sources for sugar interference with GOx glucose sensors, and thus, should be considered during device development.
电化学酶促葡萄糖传感器旨在测量血液或组织间液中的葡萄糖浓度。这类葡萄糖传感器中的一类是连续葡萄糖监测仪(CGM),用于跟踪和监测组织间液中的葡萄糖浓度变化,并作为血糖检测的辅助手段。目前获批的CGM采用葡萄糖氧化酶(GOx)电化学检测方案。潜在的干扰物会影响包括CGM在内的葡萄糖传感器所获得结果的准确性。
对七种糖类、七种糖醇类和三种人工甜味剂进行体外筛选,以检测其在高于生理浓度时对电流型葡萄糖氧化酶(GOx)传感器的干扰。使用定制的电流型系统,在生理相关浓度下进一步研究了半乳糖。此外,进行了葡萄糖和半乳糖校准实验,以促进采用多种酶动力学分析方法(米氏方程和希尔方程)来了解半乳糖干扰的潜在来源和机制。
在体外测试中,除半乳糖、木糖和甘露糖外,即使在浓度显著高于正常生理浓度时,所有筛选的化合物的干扰偏差(以平均绝对相对差异(MARD)表示)均≤20%。半乳糖的MARD在47%-72%之间,具体取决于CGM,并因此接受了进一步测试。在测试生理相关半乳糖浓度(0.1-10mg/dL)时,记录到的最高平均相对差异(MRD)为6.9±1.3%。酶动力学分析提供了CGM中酶对葡萄糖和半乳糖底物的最大反应速率(Vmax)、表观米氏常数(Km)和希尔方程h参数的计算结果。
在体外筛选条件下,17种化合物中的14种未表现出可测量的干扰。半乳糖在筛选过程中表现出最高的干扰,但在生理相关浓度的体外测试条件下,对CGM没有实质性干扰。用半乳糖进行的酶动力学分析支持了以下观点:(1)GOx酶对非葡萄糖糖类的反应性,以及(2)酶杂质(如半乳糖氧化酶)的存在是糖类干扰GOx葡萄糖传感器的两个潜在来源,因此,在设备开发过程中应予以考虑。